Frontiers in Microbiology · 2013 · 69 citations · 47 references
Life SciencesPharmacologyPharmacotherapyAntimicrobial PharmacotherapyAntimicrobial ResistanceDrug DiscoveryAntibacterial PharmacologyAntibiotic ResistanceAntibiotic Resistance MechanismsBeta-lactam ResistanceMultidrug ResistanceResistance In Gram-negative BacteriaBacterial Multidrug ResistanceBeta-lactamase Inhibitor ResistanceBeta-lactamase InhibitorsBeta-lactamase Mediated ResistanceMultidrug-resistant Gram-negative BacteriaNovel Beta-lactamase DiscoveryResistance Mechanisms In Gram-negative Bacteriaβ-Lactam Antibiotics
The increasing incidence and prevalence of multi-drug resistance (MDR) among contemporary Gram-negative bacteria represents a significant threat to human health. Since their discovery, β-lactam antibiotics have been a major component of the armamentarium against these serious pathogens. Unfortunately, a wide range of β-lactamase enzymes have emerged that are capable of inactivating these powerful drugs. In the past 30 years, a major advancement in the battle against microbes has been the development of β-lactamase inhibitors, which restore the efficacy of β-lactam antibiotics (e.g., ampicillin/sulbactam, amoxicillin/clavulanate, ticarcillin/clavulanate, and piperacillin/tazobactam). Unfortunately, many newly discovered β-lactamases are not inactivated by currently available inhibitors. Is there hope? For the first time in many years, we can anticipate the development and introduction into clinical practice of novel inhibitors. Although these inhibitors may still not be effective for all β-lactamases, their introduction is still welcome. This review focuses on the novel β-lactamase inhibitors that are closest to being introduced in the clinic.
47
Kanimozhi Kumarasamy, Mark A. Toleman, Timothy R. Walsh et al. · The Lancet Infectious Diseases · 2010 · 2.9K citations · Full text
Helen W. Boucher, George H. Talbot, Daniel K. Benjamin et al. · Clinical Infectious Diseases · 2013 · 696 citations · Full text